UroGen Pharma Ltd.

URGN

Held by 2 specialist biotech funds

Share on X

Fund Holdings

OrbiMed Advisors RTW Investments

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/ARA Capital Management0.0%Aug 14, 2025

SC 13G/ARA Capital Management7.0%May 15, 2025

SC 13G/A

Position Details

OrbiMed AdvisorsNEWFeb 17, 2026

Shares: 875,487Value: $20.5M

**Signal Note: OrbiMed Initiates $20.5M Position in UroGen Pharma** OrbiMed's entry signals confidence in UroGen's commercial execution of Jelmyto (mitomycin) for non-muscle invasive bladder cancer (NMIBC), which achieved FDA approval in late 2020 and is competing in a market historically dominated by BCG therapy amid widespread shortages. The $20.5M stake (~2.3% of outstanding shares) likely reflects conviction in near-term revenue inflection as adoption accelerates post-shortage normalization and upcoming label expansion data becomes available.

RTW InvestmentsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

NBIX2 funds APLS2 funds IRON2 funds ARGX2 funds AXSM2 funds PTCT2 funds IMA2 funds CMPS

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: RTW Investments enters URGN** RTW's substantial $106M initiation suggests conviction in UroGen's commercial execution of Jelmyto (mitomycin), the first and only FDA-approved intravesical thermochemotherapy for BCG-unresponsive non-muscle invasive bladder cancer—a high-unmet-need segment with limited options post-BCG failure. Near-term catalysts likely include uptake trajectory data, payer coverage expansion, and potential label expansions into earlier-line NMIBC indications.